will kill the transferred lymphocytes if they are exposed to the drugs acyclovir or ganciclovir (used to treat 
herpes and cytomegalovirus infections). The presence of this gene in the transferred lymphocytes may allow 
us to destroy them by giving you ganciclovir if they cause any serious side effects. If the transferred 
lymphocytes do not cause any side effects at all, but you require ganciclovir or acyclovir to treat a herpes 
virus infection developing after transplant, we will administer your lymphocytes that were not modified by the 
gene transfer technique. 
As an additional method to try to prevent HIV from spreading to the new donated bone marrow, we will 
administer the drug zidovudine. Zidovudine is a drug that has demonstrated some efficacy against HIV, 
therefore you will receive this drug beginning prior to the marrow transplant and continuing indefinitely 
following the marrow transplant. 
PROCEDURES 
The procedures you will need to undergo will be described under the three components of this therapy: 1. 
Bone marrow transplantation, 2. Zidovudine (AZT) administration, and 3. Adoptive immunotherapy with 
genetically modified HIV-specific T cells. 
1. Bone marrow transplantation 
Prior to bone marrow transplant very high doses of chemotherapy combined with total body 
irradiation (TBI) can be given in an attempt to destroy the lymphoma cells. This treatment will also 
destroy the normal bone marrow and the blood cells in your body infected with HIV. Bone marrow 
from your donor will be given to replace your destroyed marrow. 
A history and physical examination, review of your recent medical records, complete blood counts, 
appropriate x-ray studies, marrow biopsies, and other laboratory studies as needed to assess the 
current lymphoma status will be performed on you within the week before hospitalization. The drug 
allopurinol will be given to you several days before transplant to prevent kidney damage when you 
receive the chemotherapy and radiation therapy. The drug cyclophosphamide will be given 
intravenously to you to reduce the number of malignant lymphoma cells. Total body irradiation (TBI) 
also kills malignant cells and prevents you from rejecting the new marrow. TBI will be given to you 
at an exposure of 200 rads on each of six days. Bone marrow, obtained from your donor, will be 
administered to you intravenously like a blood transfusion. Some doses of methotrexate will be given 
into your spinal column (intrathecally) to treat lymphoma cells that might be present in your central 
nervous system. If you have a history of central nervous system lymphoma or active lymphoma at 
the time of transplant you will receive additional intrathecal methotrexate. Methotrexate schedules 
may vary depending on clinical response, blood counts, and other variables. Bone marrow 
aspirations, blood counts, and other laboratory tests will need to be done on you frequently in order 
to check the response to the treatment. Such testing is standard procedure for patients on 
chemotherapy. 
2. Zidovudine (AZT) administration 
The drug Zidovudine (AZT) will be given to you intravenously (in the vein) beginning approximately 
two weeks prior to BMT. At the time of BMT and for at least three weeks thereafter, it will be given 
to you intravenously. At the time of discharge, Zidovudine (AZT) will be given to you as an oral 
preparation to be taken for an indefinite period of time. Blood samples will be drawn on you as 
frequently as every two weeks for the first three months to determine drug levels, potential toxicity, 
and the status of HIV infection. Thereafter, blood samples will be drawn on you every three months. 
Recombinant DNA Research, Volume 15 
[635] 
